AstraZeneca ABApril 10, 2026

FDA 483 - AstraZeneca AB - April 10, 2026

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore AstraZeneca AB

Record Details

AstraZeneca AB in Sodertalje, Sweden, received a Form 483 with two observations related to inadequate quality control practices. The firm failed to thoroughly investigate unexplained discrepancies, such as foreign particles in tablet batches and recurring equipment performance issues, and its CAPA system was found to be insufficient in preventing the recurrence of deviations.

Company: AstraZeneca AB
Inspection Date: April 10, 2026
Product Type: Drugs
Office: Office of Partnerships
People: Rowena S. Nguyen
Allison A. Aldridge

Open in Dashboard

ID · 9e33893b-d803-4c11-bfd7-ef205dcc19d0